Marks H.L.,Texas A&M University |
Pishko M.V.,Texas A&M University |
Jackson G.W.,Biotex, Inc. |
Jackson G.W.,Base Pair Biotechnologies, Inc. |
Cote G.L.,Texas A&M University
Surface-enhanced Raman scattering (SERS) optical nanoprobes offer a number of advantages for ultrasensitive analyte detection. These functionalized colloidal nanoparticles are a multifunctional assay component. providing a platform for conjugation to spectral tags, stabilizing polymers, and biorecognition elements such as aptamers or antibodies. We demonstrate the design and characterization of a SERS-active nanoprobe and investigate the nanoparticles' biorecognition capabilities for use in a competitive binding assay. Specifically, the nanoprobe is designed for the quantification of bisphenol A (BPA) levels in the blood after human exposure to the toxin in food and beverage plastic packaging. The nanoprobes demonstrated specific affinity to a BPA aptamer with a dissociation constant Kd of 54 nM, and provided a dose-dependent SERS spectra with a limit of detection of 3 nM. Our conjugation approach shows the versatility of colloidal nanoparticles in assay development, acting as detectable spectral tagging elements and biologically active ligands concurrently. © 2014 American Chemical Society. Source
Base Pair Biotechnologies, Inc. | Date: 2012-10-15
The present invention relates to methods for generating functional biomolecules. In one exemplary aspect of the invention, generation of functional biomolecules may be performed against multiple targets simultaneously within a single system. In general, a plurality of targets may be disposed within in a single reaction volume and a library of biomolecules, such as a nucleic acid library, may be applied to the reaction volume. The members of the library that do not bind to any of the plurality of targets under given conditions may then be partitioned. The remaining members of the library may then be marked and/or tagged, such as to identify the particular target or targets to which the member of the library binds. The binding members of the library may then be isolated and, by virtue of the marking or tagging, be matched to a particular target or targets.
Base Pair Biotechnologies, Inc. | Date: 2013-01-23
The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules. The present invention further relates to methods for generating, for example, functional biomolecules, particularly to functional nucleic acids, that bind with functional activity to another biomolecule, such as a receptor molecule. More than one or multiple targets as used herein may generally include different types of targets, and/or may also include a multitude of a singular type of targets at different conditions, such as, for example, temperature, pH, chemical environment, and/or any other appropriate conditions.
Base Pair Biotechnologies, Inc. | Date: 2014-04-21
Molecular probes to particular targets may be nucleic acids that may generally possess resistance to degradation when bound to a target molecule. For example, the molecular probes may be generally resistant to nuclease degradation when bound to their target molecules, and generally not resistant to nuclease degradation when unbound to their target molecules. This may be utilized, for example, to selectively degrade unbound molecular probes while preserving the bound molecular probes, which may thus serve as an indication of the presence of their target molecules in a sample.
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: STTR | Phase: Phase I | Award Amount: 218.78K | Year: 2016
DESCRIPTION provided by applicant Neonatal and pediatric intensive care still involves performing painful needle punctures to obtain blood samples for routine clinical monitoring Pain management in the neonatal setting is often achieved by long term continuous intravenous infusion of morphine or related compounds It has become increasingly clear however that long term use of opioid compounds in neonates is likely to have significant deleterious neurological effects Unfortunately the very nature of neonates lower weight and incomplete and varied metabolic development complicates pharmacokinetic studies and modeling New analytical platforms are needed to enable studies of commonly used compounds in this patient population Non or minimally invasive microfluidic platforms with the ability to address multiple analytes in flexible manner have great promise in improving neonatal pain management and patient outcomes This project will apply a relatively new mode of detection backscattering interferometry BSI in conjunction with novel DNA aptamers binding agents to detect and quantify important opioids used for pain management in neonates as well as propofol an important agent used for general anesthesia We will also generate the necessary aptamers for detection of the urinary metabolites of these compounds The developed platform only requires microliter or less of urine and will enable studies and possibly personalized dosing of therapeutic compounds in neonates Because of our expertise to rapidly develop aptamers to small molecules in Phase II we will be in an excellent position to expand the menu of assays and translate them to the clinic with a recently developed benchtop BSI instrument PUBLIC HEALTH RELEVANCE Backscattering interferometry BSI is a recently developed technology for sensitive molecular detection developed by scientists at Vanderbilt University This project will develop a new system for rapid quantitation of pharmaceutical compounds and metabolites in the urine of newborns Because the system is microfluidic it requires less than microliter of sample and results are available in less than minute after sample introduction A new benchtop instrument has been recently developed which will allow us to rapidly translate the platform to the clinic or neonatal intensive care unit NICU in Phase II